Added text to state that the anti-PD1 monoclonal antibody nivolumab has shown an overall response rate of 87% and a complete response rate of 17%, with durations usually exceeding 1 year for heavily pretreated, relapsed patients; the rate of progression-free survival (PFS) at 24 weeks was 86% (cited Ansell et al. as reference 34 and level of evidence 3iiiDiv).
Added text to state that a phase II trial reported a response rate higher than 50% for bendamustine in relapsing patients (cited Moskowitz et al. as reference 35 and level of evidence 3iiiDiv). Also added that for patients with recurrent disease after autologous bone marrow transplantation, weekly vinblastine therapy has provided palliation with minimal toxic effects (cited Little et al. as reference 36 and level of evidence 3iiiDiv).
HL During Pregnancy
Added text to state that a multicenter retrospective analysis of 40 patients described pregnancy termination in 3 patients, deferral of therapy to postpartum in 13 patients, and antenatal therapy applied to the remaining 24 patients. Also added that with a median follow-up of 41 months, the 3-year PFS was 85%, and the overall survival was 97%, often using doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD) (cited Evens et al. as reference 16 and level of evidence 3iiiDiv).
This summary is written and maintained by the PDQ Adult Treatment Editorial Board, which is editorially independent of NCI. The summary reflects an independent review of the literature and does not represent a policy statement of NCI or NIH. More information about summary policies and the role of the PDQ Editorial Boards in maintaining the PDQ summaries can be found on the About This PDQ Summary and PDQ® – NCI’s Comprehensive Cancer Database pages.